Home > Journals > Panminerva Medica > Past Issues > Panminerva Medica 2018 March;60(1) > Panminerva Medica 2018 March;60(1):17-24



Publication history
Cite this article as


A Journal on Internal Medicine

Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,698




Panminerva Medica 2018 March;60(1):17-24

DOI: 10.23736/S0031-0808.17.03386-9


language: English

Tumor suppressor role of miR-503

Gaurav GUPTA 1, Dinesh K. CHELLAPPAN 2, Terezinha de JESUS ANDREOLI PINTO 3, Philip M. HANSBRO 4, Mary BEBAWY 5, Kamal DUA 5

1 School of Pharmaceutical Sciences, Jaipur National University, Jagatpura, Jaipur, India; 2 Department of Life Sciences, School of Pharmacy, International Medical University, Kuala Lumpur, Malaysia; 3 Department of Pharmacy, Faculty of Pharmaceutical Sciences, University of São Paulo, São Paulo, Brazil; 4 School of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan, Australia; 5 Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Ultimo, Australia


MicroRNAs (miRNAs) are non-coding RNAs of around 20-25 nucleotides in length with highly conserved characteristics. They moderate post-transcriptional silencing by precisely combining with 3’ untranslated regions (UTRs) of target mRNAs at a complementary site. miR‑503, an associate of the “canonical” miRNA-16 family, is expressed in numerous types of tumors such as breast cancer, prostate cancer, lung cancer, colorectal cancer, hepatocellular carcinoma, glioblastoma and several others. There is convincing evidence to show that miR‑503 functions as a tumor suppressor gene through its effects on target genes that regulate cell proliferation, migration, and invasion in tumor cells. In this current assessment, we discuss the biology and tumor suppressor role of miR‑503 in different cancers and elaborate on its mechanism of action.

KEY WORDS: Neoplasms - MIRN503 microRNA - Genes, tumor suppressor

top of page

Publication History

Issue published online: February 15, 2018
Article first published online: November 22, 2017
Manuscript accepted: November 14, 2017
Manuscript received: November 9, 2017

Cite this article as

Gupta G, Chellappan DK, de Jesus Andreoli Pinto T, Hansbro PM, Bebawy M, Dua K. Tumor suppressor role of miR-503. Panminerva Med 2018;60:17-24. DOI: 10.23736/S0031-0808.17.03386-9

Corresponding author e-mail